Related Experiment Videos
Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy
Makoto Uchino1, Satoshi Yamashita, Katsuhisa Uchino
1Department of Neurology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. uchino@jonan-hospital.or.jp
Background:
We previously reported no difference in the efficacies of high-dose alternate-day (ADT) and daily-dose (DDT) prednisolone therapies in myositis patients, but that the incidence of side effects was lower in the former. The aim of the present study was to compare the long-term outcomes of both treatments in polymyositis patients.
Methods:
We compared clinical courses, efficacies, adverse reactions, and outcomes of 115 consecutive, biopsy-proven polymyositis patients treated between 1970 and 2008 with ADT (32 patients) or DDT (83 patients).
Results:
Mean onset ages, disease severity, incidences of malignancy, and response rates did not differ between the ADT and DDT groups. Adverse reactions (incidence of diabetes) were significantly higher in the DDT group. In this group, the incidences of hyperlipidemia, infection, hypertension, and psychiatric symptoms were also slightly higher, but not significantly so. The 20-year survival rate of the ADT group (68%) was significantly higher (p = 0.0112) than that of the DDT group (37%).
Conclusion:
ADT might be useful as an initial treatment option for polymyositis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myocarditis IV: Nursing Management
Myocarditis III: Medical Management
Long-term Potentiation
COPD: Management Using Bronchodilators and Corticosteroids